SAD
| Biological agent
| Infections
|
|---|---|---|
Churg-Strauss |
RITUXIMAB |
recurr respiratory infect (1) |
Churg-Strauss |
RITUXIMAB |
bronchoneumonia (ns) + zoster |
Cryioglobulinemia |
RITUXIMAB |
Pat 1: fascitis (ns) and meningoencephalitis (criptococ); Pat 2: systemic herpes (HS type 2) |
Cryioglobulinemia |
RITUXIMAB |
Severe pneumonia (UCI), posterior second severe pneumonia (S Aureus) |
Cryioglobulinemia |
RITUXIMAB |
one septic fever of probable bacterial origin |
DM |
RITUXIMAB |
Skin (2), bronchitis (3), sinusitis (2), UTI (1), otitis (1) |
Systemic sclerosis |
RITUXIMAB |
Pat1: pneumonia x 2 and sepsis (ns); Pat 2: zoster |
SLE |
RITUXIMAB |
Thigh herpes zoster (1) |
SLE |
RITUXIMAB |
Herpes zoster temporal (1) |
SLE |
RITUXIMAB |
respiratory infections (3), pneumococcal meningitis (1) |
SLE |
RITUXIMAB |
Endocarditis (strepto viridans) |
SLE |
RITUXIMAB |
Pneumonia (2), zoster (1), varicella (1), cut ulcers (1) |
SLE |
RITUXIMAB |
Zoster (1), UTI (1) |
SLE |
RITUXIMAB |
Zoster (1), UTI (1) |
SLE |
RITUXIMAB |
Pneumonia pneumoc (1) |
SLE |
RITUXIMAB |
Development of LMP (included in the FDA alert) |
SLE |
RITUXIMAB |
Sepsis (Ps aeruginosa) |
Sjögren |
RITUXIMAB |
Herpes zoster (1) |
Wegener |
RITUXIMAB |
respiratory infection (1) (ns) |
Wegener-MPA |
RITUXIMAB |
respiratory infection (2), zoster (1) |
Wegener-MPA |
RITUXIMAB |
respiratory infections (5), influenza (1), zoster (2) |
Wegener |
RITUXIMAB |
septic arthritis (1), respiratory infections (2) |